A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of Oral VH4524184 Coadministered With Emtricitabine and Tenofovir Alafenamide in Treatment Naive Viremic Persons With HIV-1 (INNOVATE Study)

This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC/TAF), to a standard HIV treatment called dolutegravir and lamivudine (DTG/3TC). The purpose of the study is to provide data on the long-term antiviral activity of the VH4524184 and provide information regarding dosing formulation for further evaluations.

开始日期2026-02-06

申办/合作机构

ViiV Healthcare Ltd.

NCT07349758

/ Recruiting临床1期IIT

DD-PrEP: Pharmacokinetic Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers

The goal of this study is to evaluate the pharmacokinetics of a one-time dosing of two F/TAF tablets over a 14-day period.

开始日期2026-01-01

申办/合作机构

The Johns Hopkins University

[+1]

CTR20253999

/ Recruiting临床3期

评估ACC017片在初治人类免疫缺陷病毒1型（HIV-1）成人中有效性和安全性的多中心、随机、双盲双模拟、多替拉韦钠片对照的Ⅲ期研究

评估48周时，ACC017组相比于多替拉韦钠组的病毒学有效性（HIV RNA载量＜50 copies/mL参与者百分比）。

开始日期2025-11-04

申办/合作机构

江苏艾迪药业集团股份有限公司

[+3]

100 项与恩曲他滨/富马酸磷丙替诺福韦相关的临床结果

登录后查看更多信息

100 项与恩曲他滨/富马酸磷丙替诺福韦相关的转化医学

登录后查看更多信息

100 项与恩曲他滨/富马酸磷丙替诺福韦相关的专利（医药）

登录后查看更多信息

项与恩曲他滨/富马酸磷丙替诺福韦相关的文献（医药）

2026-01-01·CLINICAL MICROBIOLOGY AND INFECTION

Randomized clinical trial to evaluate the longitudinal HIV-1 reservoir and inflammation in treatment-naïve people starting dolutegravir/lamivudine versus dolutegravir plus tenofovir alafenamide/emtricitabine

Article

作者: Gutierrez-Valencia, Alicia ; Roca-Oporto, Cristina ; Trujillo-Rodriguez, María ; Raffo-Marquez, Miguel ; Alvarez-Ríos, Ana I ; Espinosa, Nuria ; Rivero, Antonio ; Mariscal-Vázquez, Gabriel ; Romero-Palacios, Alberto ; Serna-Gallego, Ana ; Herrero, Marta ; Lopez-Cortes, Luis E ; Muñoz-Muela, Esperanza ; Sotomayor, Cesar ; Saborido-Alconchel, Abraham ; Lopez-Cortes, Luis F

OBJECTIVE:

There is limited evidence on whether dolutegravir/lamivudine (DTG/3TC) reduces the viral reservoir, immune activation, and inflammation as a three-drug regimen. This study aims to clarify possible differences in these outcomes in people with HIV-1 (PHIV) starting DTG plus tenofovir alafenamide/emtricitabine (DTG + TAF/F) versus DTG/3TC.

METHODS:

A phase IV, controlled, open-label, multicentre clinical trial in which treatment-naïve PHIV were randomized to DTG + TAF/F or DTG/3TC. The primary endpoint was changes in CD4⁺ T cells associated with HIV-1-DNA and HIV-1-RNA after 12 and 24 months (Intact Proviral DNA and Intact Viral RNA Assays). Secondary endpoints included immune recovery and changes in T-cell phenotypes and plasma inflammatory markers.

STATISTICS:

χ², Mann-Whitney U test, and general linear model for repeated measures.

RESULTS:

Sixty-six participants were randomized, of whom 30 (DTG/3TC) and 29 (DTG + TAF/F) completed follow-up. Overall, the median baseline CD4⁺/μL count was 401 (293-540), the CD4⁺/CD8⁺ ratio 0.47 (0.34-0.76), and the viral load 57 250 copies/mL (16 189-180 500). Results are reported as medians (interquartile ranges) in the DTG + TAF/F and DTG/3TC groups at baseline and month 24, respectively. Intact HIV-1-DNA: 1210 (412-3508) copies/10⁶ CD4⁺ and 1230 (335-2502), which decreased to 65 (24-236) and 71 (32-110) (F = 0.253; p = 0.691). Total defective HIV-1-DNA: 831 copies/10⁶ CD4⁺ (315-1636) and 726 (273-1770), decreasing to 143 copies/10⁶ CD4⁺ (82-368) and 266 (67-353) (F = 1.840, p = 0.201). Similarly, no significant differences were observed between the groups in immune recovery, decrease in activation, proliferation, and exhaustion markers of T cells, as well as in the reduction of plasma levels of interleukin-1β, interleukin-6, tumour necrosis factor-α, interferon-γ, sCD14, and sCD163.

CONCLUSIONS:

These data suggest that starting treatment with DTG + TAF/F does not confer benefits over DTG/3TC.

2025-08-01·HEALTH AFFAIRS

Insurance Denials And Cost Sharing For PrEP Among Sexual And Gender Minority People

Article

作者: D’Angelo, Alexa ; Grov, Christian ; Mirzayi, Chloe ; Carrico, Adam W. ; Tsui, Emma K. ; Zewde, Naomi

Despite coverage regulations requiring most insurers to cover pre-exposure prophylaxis (PrEP) without cost sharing, insurance coverage issues and cost-sharing practices persist. In this study, we assessed the prevalence of denials and cost sharing associated with PrEP among sexual and gender minority people in the US. Between August 2022 and July 2023, we recruited, via geosocial networking applications, sexual and gender minority people, who completed a screening survey for an HIV prevention study. Of 11,410 participants reporting current or former PrEP use, 23.7 percent had ever experienced a denial for their PrEP, ranging from 8.5 percent for generic tenofovir disoproxil fumarate and emtricitabine to 48.2 percent for Descovy. In addition, 34.6 percent reported cost sharing within the prior two years. The majority (58.3 percent) of cost-sharing instances were for laboratory bloodwork, and most (61.5 percent) were among privately insured people. Continued insurance denials and cost sharing associated with PrEP necessitate further policy intervention to address gaps in coverage, billing errors, and challenges resulting from formulary tiering.

2025-05-01·Journal of the International AIDS Society

No significant drug−drug interaction between oral TAF‐based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT‐3 study

Article

作者: Boonruang, Jakkrapatara ; Hongchookiat, Piranun ; Thammajaruk, Narukjaporn ; Kerr, Stephen ; Cressey, Tim R. ; Anderson, Peter L. ; Teeratakulpisarn, Nipat ; Tawon, Yardpiroon ; Trichavaroj, Rapee ; Phanuphak, Nittaya ; Hiransuthikul, Akarin ; Nonenoy, Siriporn ; Janamnuaysook, Rena

Abstract:

Introduction:

Concerns regarding potential drug−drug interaction (DDI) between feminizing hormone therapy (FHT) and HIV pre‐exposure prophylaxis (PrEP) may hinder PrEP use among transgender women. We assessed the potential DDI between FHT and emtricitabine‐tenofovir alafenamide (F/TAF)‐based PrEP among transgender women.

Methods:

Transgender women without HIV who never underwent orchiectomy were enrolled between January and February 2022. Oral FHT (oestradiol valerate 2 mg and cyproterone acetate 25 mg) was initiated at baseline and continued until week 9, while oral PrEP (F/TAF 200/25 mg) was initiated at week 3 and continued until week 12. Intensive blood sampling was performed at weeks 3 and 9 to assess the impact of PrEP on FHT; and weeks 9 and 12 to assess the impact of FHT on PrEP. Pharmacokinetics (PKs) of plasma oestradiol (E2), TAF, tenofovir (TFV) and emtricitabine (FTC); urine TFV and FTC; and tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP) in peripheral blood mononuclear cells (PBMCs) and rectal tissues were assessed.

Results:

Eighteen participants completed all PK visits. No significant differences in PK parameters for plasma E2, TAF and TFV were observed with FHT and F/TAF administration. The geometric mean of FTC AUC0−24 at week 9 was 9% lower than at week 12, but the 90% CI (0.88−0.95) remained within the 80–125% range. There were no significant differences in PBMCs and rectal tissues TFV‐DP and FTC‐TP concentrations when F/TAF was administered with FHT.

Conclusions:

No bidirectional clinically significant DDI between FHT and F/TAF‐based PrEP was observed across systemic and local tissue anatomical compartments, supporting the use of oral F/TAF‐based PrEP among transgender women.

Clinical Trial Number:

NCT04590417

214

项与恩曲他滨/富马酸磷丙替诺福韦相关的新闻（医药）

2026-01-13

·Pharmaceutical Technology

JPM26: HIV pipeline dosing optionality gives Gilead advantage

Gilead’s CEO Daniel O’Day presented at the J.P. Morgan Healthcare Conference on 12 January. Image credit: ETIENNE LAURENT / AFP via Getty Images Gilead’s range of treatments and prevention for human immunodeficiency virus (HIV), both on the market and in the pipeline, provides the company a competitive edge, CEO Daniel O’Day believes. Speaking at the J.P. Morgan Healthcare Conference 2026, which is taking place in San Francisco from 12 to 15 January 2026, O’Day explained that in HIV, the company has seven candidates and combinations in the pipeline, offering a range of treatment options for patients in both treatment with anti-retroviral therapies (ART) and prevention with pre-exposure prophylaxis (PrEP), which all offer varying dosing schedules and administration methods. O’Day said: “We have significantly expanded and diversified our pipeline with a range of options because if there’s one thing we know in HIV, it’s that patients want options. People who want to prevent HIV want options that fit their life and their lifestyle, particularly as we have transformed this disease from a death sentence to a preventable long-term, chronic illness.” While the company has already made a name for itself in HIV, especially with its newest PrEP treatment Yeztugo (lenacapavir), which is a twice-yearly injectable PrEP that touted 100% and 99% protection against the virus in two Phase III trials, it is continuing to develop its pipeline. Seven Gilead candidates are either in trials or awaiting regulatory decisions. Lenacapavir is also marketed under the name Sulenca when used as an ART. This includes a daily oral treatment, which is a combination of Gilead’s bictegravir and lenacapavir (BIC/LEN), for which it expects a regulatory decision in H2 2026. Full data from the Phase III ARTISTRY programme is due to be released in H1 2026. The company also expects to present data from two Phase III trials (NCT06630286 and NCT06630299) of a weekly oral combination of MSD’s islatravir and Gilead’s lenacapavir in H1 2026, with hopes that this would prepare the company for a 2027 launch. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Back in PrEP, Gilead is hoping for a 2028 launch of its once-yearly lenacapavir , if the regimen demonstrates success in clinical trials. Following its launch of Yeztugo in the US in mid-2025, the drug brought in $150m in preliminary sales in 2025, meeting its 2025 guidance. The PrEP also has 85% payer coverage in the US, with it being available with a $0 copay on some policies. O’Day said: “We take our responsibility in terms of ending the epidemic very, very seriously, so in addition to making progress in this country with the Yeztugo launch, I am very pleased that lenacapavir was delivered for the first time ever in a sub-Saharan African country at the end of last year, in the same year as it was introduced in the US. That has never been done before. We know that two-thirds of HIV cases are in sub-Saharan Africa. If we don’t stop HIV everywhere, we won’t stop it anywhere.” On top of new launches, Gilead still has some protection of its marketed therapies, with its flagship HIV ART, Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide), not losing exclusivity until 2036. The company will lose exclusivity of Descovy (emtricitabine/tenofovir alafenamide) in 2031. GlobalData, the parent company of Pharmaceutical Technology , predicts a combined patient-based sales forecast for Yeztugo and Sulenca of $4.98bn in 2033. The HIV market across the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan) is forecast to grow at a compound annual growth rate (CAGR) of 1.9% from $26.5bn in 2023 to $32.1bn in 2033, forecasts GlobalData . Sign up here to receive daily updates on the latest healthcare industry trends emerging from the JP Morgan Healthcare Conference 2026. Sign up here to receive a comprehensive report after the conference.

临床3期

2026-01-05

·全球药查查

达可辉是什么药物？达可辉和必妥维的区别？

每天只需一片药，艾滋病治疗进入“简便时代”，但面对不同方案，患者该如何做出明智选择？深夜，一位刚被诊断为 HIV 感染的患者在病友群里询问：“医生推荐了必妥维，但我听说达可辉副作用小，到底该选哪个？” 一时间，群里众说纷纭，但大多信息混乱不完整。 01 药物辨析：被误解的“达可辉”与常见混淆你可能听过“达可辉”这个名字，但事实上，这是一个常见的误称或混淆。在艾滋病治疗领域，真正的名称是 “达可挥”（Descovy），它是恩曲他滨丙酚替诺福韦片的商品名。另一个常被提及的药物“达必妥”，实际上与艾滋病治疗完全无关，它是一种治疗特应性皮炎的靶向生物制剂。这个混淆恰恰反映出许多患者面临的困境：面对复杂的药物名称、多样的治疗方案，如何在信息混杂的环境中做出明智选择？艾滋病治疗已从昔日的“多药多时”转变为如今的“一日一片”，但选择合适的药物方案，仍然需要基于对药物的全面了解。 02 核心解析：达可挥到底是什么药物？达可挥（Descovy）是一种固定剂量的复方制剂，属于艾滋病治疗中的“骨干药物”，但它本身并非一个完整的治疗方案。这种药物由两种关键成分组成：恩曲他滨（200mg）和丙酚替诺福韦（25mg）。这两种药物均属于核苷类逆转录酶抑制剂，是抗艾滋病治疗中的基础组合。达可挥在艾滋病治疗中扮演着 “骨架”角色，需要与另一类核心药物（通常是整合酶抑制剂或蛋白酶抑制剂）联合使用，才能构成完整的治疗方案。这种药物组合因其对肾脏和骨骼的毒性较小而受到关注。与传统替诺福韦配方相比，丙酚替诺福韦在体内的靶向性更强，能够在淋巴组织中达到更高浓度，同时减少对其他器官的影响。然而，达可挥不能单独作为治疗方案使用。在实际临床应用中，医生会根据患者的具体情况，将其与比克替拉韦（构成必妥维）或多替拉韦等核心药物联合使用，形成完整的抗病毒方案。 03 全面了解：必妥维是怎样的艾滋病治疗方案？与达可挥不同，必妥维（Biktarvy）是一种 “完整的三合一”抗艾滋病方案，患者每日只需服用一片，无需再搭配其他抗病毒药物。它的成分包括比克替拉韦（50mg）、恩曲他滨（200mg）和丙酚替诺福韦（25mg）。这里的比克替拉韦是一种新型整合酶链转移抑制剂，是必妥维发挥强大抗病毒作用的核心成分。作为一种完整方案，必妥维同时包含了艾滋病治疗中的“核心药物”和“骨干药物”，形成了一种基于整合酶抑制剂的最小化三联复方单片制剂。研究显示，必妥维在初治患者和已经实现病毒学抑制的经治患者中，均能实现非常高的病毒学抑制率，且迄今没有观察到因使用该药而产生耐药性的情况。在2022年，必妥维被正式纳入中国国家医保目录，价格也从最初的高位显著下降，使更多患者能够获得这一先进治疗方案。2024年后，其价格进一步下调至每瓶（30片）933元左右。 04 关键区别：达可挥与必妥维的多维度对比表面上看，这两种药物都用于艾滋病治疗，都含有恩曲他滨和丙酚替诺福韦，但在本质上有显著差异。从成分和性质上看，达可挥是双药组合，而必妥维是三药组合。这一差别决定了它们在治疗方案中的不同地位。这就像建房，达可挥提供了坚固的“地基和框架”，而必妥维是已经建好的“完整房屋”，可以直接入住。在治疗方案上，达可挥必须与其他核心抗病毒药物联合使用，而必妥维本身就是一个完整的治疗方案，无需额外搭配其他抗艾滋病药物。适应症方面，达可挥作为“骨架药物”适用于需要定制化治疗方案的特定患者群体，而必妥维则适用于绝大多数HIV-1感染患者，包括初治人群和需要换药的患者。值得注意的是，必妥维还能覆盖合并乙肝感染的情况，而仅使用达可挥的双药方案通常建议在经过耐药基因检测及排除HBV合并感染后使用。在用药便利性上，必妥维作为完整的三合一片剂，每日只需服用一次，且无需考虑食物影响，大大简化了用药过程。而使用达可挥的联合方案可能需要服用多片药物，管理更为复杂。 05 疗效与安全性：两种方案的临床表现差异从疗效数据来看，必妥维展现出了强大的病毒抑制能力。一项临床研究显示，使用必妥维治疗的初治患者中，有98%在第48周时仍能维持病毒学抑制。在长期研究中，必妥维也显示出持久的疗效和良好的耐受性。接受必妥维初始治疗的HIV感染者，能实现非常高的病毒抑制率。安全性方面，两种药物均含有丙酚替诺福韦，这种成分相较于传统的替诺福韦配方，对肾功能和骨密度的影响更小。达可挥因避免长期使用替诺福韦，可能进一步减少肾脏与骨骼方面的风险，适合部分有肾功能减退或骨质疏松风险的患者。两种药物的常见副作用包括头痛、失眠、胃肠道不适等，但总体而言，它们都属于耐受性较好的艾滋病治疗方案。特别值得关注的是，必妥维还具有暴露后预防的用途，可用于高危行为后的紧急阻断，但必须在接触后72小时内开始服用，并连续使用28天。 06 患者决策：如何根据自己的情况做出选择面对两种不同的药物方案，患者应如何做出选择？首先需要明确的是，这一决定必须在专业医生的指导下进行，不可自行判断。如果你是新确诊的HIV感染者，且没有已知的耐药情况，必妥维作为一种完整的一线治疗方案，具有使用简便、疗效确切、耐药屏障高的优势，可能是优先考虑的选项。对于已经有肾功能减退、骨质疏松风险或对某些药物成分可能不耐受的患者，医生可能会考虑使用包含达可挥的定制化方案，以便更灵活地调整药物组合。经济因素也是重要的考虑点。尽管必妥维已纳入医保并多次降价，但每瓶约933元的价格，相较于免费药物方案仍有经济压力。患者需要根据自身医保覆盖情况和经济能力做出选择。患者的用药习惯和生活方式同样值得考虑。对于希望简化用药、提高依从性的患者，每日一次的单片方案（如必妥维）可能更为适合。真正的选择智慧在于理解：没有“最好”的药物，只有“最适合”的方案。一位选择必妥维的患者在坚持治疗一年后，病毒载量成功降至检测不到的水平，而他的朋友使用基于达可挥的定制方案，也达到了同样的治疗效果。选择不同，终点却一致。当医生面对选择困难的患者时，平静地展开一张对比表格：“达可挥是‘骨架’，需要‘血肉’填充；必妥维是‘完整生命体’，直接就能运作。” 愿天下无癌分享收藏点赞在看

临床研究财报

2025-12-21

·道道之道

【本周医刊】2025年第51周医学期刊更新

2025年第51周（2025.12.14-2025.12.20）重要医学期刊论著更新如下： 1.综合期刊 LANCET 题目：Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial 翻译：口服小分子胰高糖素样肽 - 1 受体激动剂奥福格列肽治疗2 型糖尿病合并肥胖症：ATTAIN-2Ⅲ期、双盲、随机、多中心、安慰剂对照临床试验题目：Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial 翻译：可切除及交界可切除Ⅰ-Ⅲ期胰腺导管腺癌术前改良氟尿嘧啶+ 亚叶酸钙+ 伊立替康+ 奥沙利铂方案（mFOLFIRINOX）对比帕博利珠单抗+ 白蛋白结合型紫杉醇+ 吉西他滨方案（PAXG）：PACT-21 CASSANDRA 随机、开放标签、2×2析因设计Ⅲ期临床试验首次随机分析结果题目：Comparison of inhalational methoxyflurane, intranasal fentanyl, and intravenous morphine for treatment of prehospital acute pain in Norway (PreMeFen): a randomised, non-inferiority, three-arm, phase 3 trial 翻译：吸入用甲氧氟烷、鼻用芬太尼与静脉用吗啡治疗挪威院前急性疼痛的疗效对比：PreMeFen随机、非劣效性、三臂Ⅲ期临床试验题目：Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China 翻译：异基因 CD19 嵌合抗原受体自然杀伤细胞（CAR-NK）疗法治疗系统性红斑狼疮的有效性与安全性：中国病例系列研究 NEW ENGLAND JOURNAL OF MEDICINE 题目：ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer 翻译：循环肿瘤 DNA 指导的阿替利珠单抗辅助治疗肌层浸润性膀胱癌题目：Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes 翻译：替尔泊肽对比度拉糖肽治疗 2 型糖尿病的心血管结局题目：Noninferiority of One HPV Vaccine Dose to Two Doses 翻译：人乳头瘤病毒疫苗单剂接种非劣效于两剂接种题目：Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis 翻译：大剂量口服利福平治疗成人结核性脑膜炎的临床试验 BMJ-BRITISH MEDICAL JOURNAL 题目：Changes in hospital financial performance and quality of care after real estate investment trust acquisition 翻译：房地产投资信托基金收购后医院财务绩效与医疗质量的变化 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 题目：An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial 翻译：人工智能驱动的生活方式干预对比人工指导在糖尿病预防项目中的应用：一项随机临床试验题目：Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score 翻译：序贯器官衰竭评估（SOFA）-2评分的建立与验证题目：Arsenic Exposure Reduction and Chronic Disease Mortality 翻译：砷暴露水平降低与慢性病死亡风险的关联 NATURE MEDICINE 题目：Detection of undiagnosed liver cirrhosis via AI-enabled electrocardiogram: a pragmatic, cluster-randomized clinical trial 翻译：基于人工智能心电图的未确诊肝硬化筛查：一项务实性整群随机临床试验 LANCET DIGITAL HEALTH 题目：Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer 翻译：乳腺癌低标注量计算法肿瘤浸润淋巴细胞评估（ECTIL研究）：基于2340 例乳腺癌患者的多中心验证题目：The impact of artificial intelligence-driven decision support on uncertain antimicrobial prescribing: a randomised, multimethod study 翻译：人工智能驱动决策支持系统对不确定性抗菌药物处方行为的影响：一项随机化多方法研究题目：Automated retinal image analysis systems to triage for grading of diabetic retinopathy: a large-scale, open-label, national screening programme in England 翻译：自动视网膜图像分析系统用于糖尿病视网膜病变分级分诊：一项英格兰大规模开放标签全国性筛查项目题目：Efficacy of standalone smartphone apps for mental health: an updated systematic review and meta-analysis 翻译：独立智能手机心理健康应用程序的效能：一项更新的系统综述与荟萃分析 NPJ DIGITAL MEDICINE 题目：Interpretable deep learning for multicenter gastric cancer T staging from CT images 翻译：基于可解释性深度学习的多中心胃癌计算机断层扫描（CT）T分期评估题目：Predicting Invasiveness of Lung Adenocarcinoma from Chest CT with Few-shot Vision-Language Ternary Classification Model 翻译：基于小样本视觉 - 语言三元分类模型的胸部CT 预测肺腺癌侵袭性题目：The structure-preserving spectral graph neural network for dual kinase inhibitors and synergy scoring in gastric cancer 翻译：用于胃癌双激酶抑制剂筛选及协同评分的结构保留谱图神经网络题目：Bridging clinical knowledge and AI: an interpretable transformer framework for ECG diagnosis 翻译：融合临床知识与人工智能：一种用于心电图诊断的可解释性Transformer 框架题目：RMS: a ML-based system for ICU respiratory monitoring and resource planning 翻译：RMS 系统：基于机器学习的重症监护病房（ICU）呼吸监测与资源规划系统题目：Systematic review and meta-analysis of regulator-approved deep learning systems for fundus diabetic retinopathy detections 翻译：监管机构批准的深度学习眼底糖尿病视网膜病变检测系统的系统综述与荟萃分析题目：An AI-powered tongue image model for home-based monitoring of liver fibrosis 翻译：基于人工智能舌象模型的居家肝纤维化监测题目：Artificial intelligence-driven multivariate integration for pulmonary arterial pressure prediction in pulmonary hypertension 翻译：人工智能驱动的多变量整合模型预测肺动脉高压患者肺动脉压力题目：Effects of app delivered self hypnosis on stress management 翻译：应用程序介导的自我催眠对压力管理的效果题目：An Automated Classifier of Harmful Brain Activities for Clinical Usage Based on a Vision-Inspired Pre-trained Framework 翻译：基于视觉启发预训练框架的临床用有害脑电活动自动分类器 2.肿瘤学 CA-A CANCER JOURNAL FOR CLINICIANS 题目：Bridging the cancer divide: Policy and structural solutions for equity in the United States 翻译：弥合癌症医疗鸿沟：美国实现医疗公平的政策与结构性解决方案 ANNALS OF ONCOLOGY 题目：Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial 翻译：卡匹沙替尼联合紫杉醇一线治疗转移性三阴性乳腺癌：全球多中心Ⅲ期随机对照CAPItello-290 试验结果题目：The Achilles heel of precision AKT-targeted therapies in advanced prostate cancer: therapeutic promise constrained by the test 翻译：晚期前列腺癌精准靶向 AKT 治疗的阿喀琉斯之踵：检测方法限制治疗潜力发挥题目：Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 翻译：局限性及局部区域性前列腺癌：欧洲肿瘤内科学会（ESMO）诊断、治疗与随访临床实践指南题目：Germline alterations in patients with lung cancer 翻译：肺癌患者的胚系基因变异特征题目：Next-Generation Multicenter Studies: Using Artificial Intelligence to Automatically Process Unstructured Health Records of Patients with Lung Cancer across Multiple Institutions 翻译：新一代多中心研究：基于人工智能自动化处理多中心肺癌患者非结构化健康医疗记录 JOURNAL OF CLINICAL ONCOLOGY 题目：Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial 翻译：三阴性乳腺癌新辅助化疗在紫杉类 - 蒽环类序贯方案基础上加用卡铂的疗效：一项Ⅲ期随机对照试验题目：Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial 翻译：新辅助药物 TQB2102 治疗局部晚期或早期人表皮生长因子受体2 阳性乳腺癌的有效性与安全性：一项随机、开放标签、多中心Ⅱ期试验题目：Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer 翻译：共识分子亚型作为 RAS 野生型转移性结直肠癌一线治疗生物标志物的个体患者数据荟萃分析题目：Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study 翻译：奎扎替尼治疗初诊 FLT3 基因内部串联重复阴性急性髓系白血病：随机、双盲、安慰剂对照Ⅱ期QUIWI 研究题目：Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2 翻译：阿米万他单抗联合拉泽替尼治疗罕见表皮生长因子受体（EGFR）突变晚期非小细胞肺癌：CHRYSALIS-2研究结果 LANCET ONCOLOGY（本周无更新） NATURE CANCER（本周无更新） JAMA ONCOLOGY 题目：Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy: A Phase 2 Randomized Clinical Trial 翻译：前列腺特异性膜抗原正电子发射断层显像引导的前列腺癌根治术后挽救性放疗剂量强化：一项Ⅱ期随机临床试验题目：The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials 翻译：结肠癌治愈的定义界定：基于 15 项随机临床试验的汇总分析题目：Risk Factors for Valvulopathy Among Childhood Cancer Survivors 翻译：儿童癌症幸存者心脏瓣膜病的危险因素题目：Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women 翻译：致病性基因变异、家族史与美国女性乳腺癌的累积发病风险题目：Artificial Intelligence–Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti–PD-1–Based Treated Melanoma 翻译：人工智能检测的肿瘤浸润淋巴细胞与程序性死亡受体1（PD-1）抑制剂治疗黑色素瘤的预后关联题目：Risk Prediction Model for Development of Heart Failure or Cardiomyopathy After Breast Cancer Treatment 翻译：乳腺癌治疗后心力衰竭或心肌病发病风险预测模型题目：Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality 翻译：坚持遵循体力活动指南与消化系统癌症发病及死亡风险的关联题目：Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women 翻译：激素避孕药剂型与青少年及绝经前女性乳腺癌发病风险 CANCER RESEARCH 题目：The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer 翻译：脯氨酰异构酶 PIN1 调控胰腺癌成纤维细胞分化状态及细胞间互作题目：Interaction and Reciprocal Stabilization of H3.3 and PARP1 Promote DNA Damage Repair and Tumor Progression in Small Cell Lung Cancer 翻译：H3.3 与PARP1 的相互作用及双向稳定促进小细胞肺癌DNA 损伤修复与肿瘤进展题目：The Microbial Bile Acid Metabolite 3-Oxo-LCA Inhibits Colorectal Cancer Progression 翻译：微生物胆汁酸代谢产物 3 - 氧代- 石胆酸抑制结直肠癌进展题目：Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma 翻译：巨噬细胞与肿瘤共进化的细胞类型特异性定量免疫肽组分析揭示胶质母细胞瘤的治疗性MHC-Ⅰ类分子结合肽题目：circADAMTS12 Inhibits the Antitumor Activity of Microglia to Enable Metastatic Colonization in the Brain 翻译：环状 RNA ADAMTS12 抑制小胶质细胞抗肿瘤活性以促进结肠癌脑转移定植题目：Surgery-Induced Neutrophil Extracellular Traps Promote Tumor Metastasis by Reprogramming Cancer Cell Lipid Metabolism 翻译：手术诱导的中性粒细胞胞外陷阱通过重编程癌细胞脂质代谢促进肿瘤转移题目：An Olive Oil–Based High-Fat Diet Promotes Obesity-Driven Metastasis of Triple-Negative Breast Cancer 翻译：橄榄油基高脂饮食促进肥胖相关三阴性乳腺癌转移题目：Parkin Induces Ubiquitination and Large Extracellular Vesicle Release of HMGB1 to Activate Antitumor Immunity 翻译：帕金蛋白诱导高迁移率族蛋白 B1 泛素化及大细胞外囊泡释放以激活抗肿瘤免疫题目：Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma 翻译：抑制 GSK3 与TSC2 介导AKT 在肝细胞癌中的促癌活性题目：Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma 翻译：弥漫大 B 细胞淋巴瘤患者治疗前外周血中独特的细胞与分子特征与嵌合抗原受体T 细胞（CAR-T）治疗疗效相关题目：Spatially Discontinuous Mutation Topographies in Ductal Carcinoma In Situ Reveal Noncompetitive Growth Dynamics 翻译：导管原位癌中空间非连续的突变图谱揭示非竞争性生长动力学特征题目：Path2Omics Enhances Transcriptomic and Methylation Prediction Accuracy from Tumor Histopathology 翻译：Path2Omics 工具基于肿瘤组织病理学特征提升转录组与甲基化预测精度题目：Mathematical Modeling Quantifies “Just-Right” APC Inactivation for Colorectal Cancer Initiation 翻译：数学建模量化结直肠癌发生过程中腺瘤性息肉病基因（APC）的“适度”失活效应题目：Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer 翻译：人工智能与多模态数据整合解析胃癌三级淋巴结构成熟度题目：Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules 翻译：大规模 T 细胞受体库测序揭示用于诊断性质待定肺结节的肿瘤特异性信号 CLINICAL CANCER RESEARCH 题目：Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study 翻译：伊布替尼治疗慢性淋巴细胞白血病患者中联合伊纳鲁单抗（VAY736）的疗效：一项Ⅰb期研究结果题目：Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC 翻译：细胞外基质 - 髓源性癌症相关成纤维细胞特征与HPV 阳性头颈部鳞状细胞癌患者对度伐利尤单抗联合二甲双胍新辅助程序性死亡配体1（PD-L1）免疫检查点抑制剂治疗耐药相关题目：Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma—An Exploratory Analysis of the STIC CTC Trial 翻译：循环肿瘤细胞在浸润性小叶乳腺癌中的预后意义及预测价值——STIC CTC 试验的探索性分析题目：ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial 翻译：局部晚期直肠癌全程新辅助治疗及非手术治疗期间循环肿瘤DNA 的纵向分析：NOMINATE试验的生物标志物研究题目：LRP1bLoss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial 翻译：LRP1b基因缺失预测非小细胞肺癌患者对免疫治疗的敏感性：Ⅲ期CheckMate-026 随机试验分析题目：Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-β Activity Driving Tumor Recurrence 翻译：前列腺癌外照射放疗前的放射基因组学分析发现转化生长因子-β（TGF-β）活性相关转录组特征驱动肿瘤复发题目：Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma 翻译：肿瘤微小 RNA 特征与Ⅱ/Ⅲ期黑色素瘤患者预后相关题目：Diagnosis and Treatment Response Monitoring of Liver Cancer Using Glypican-3–Targeted Single-Domain Antibody PET 翻译：基于磷脂酰肌醇蛋白聚糖 3 靶向单域抗体正电子发射断层显像的肝癌诊断及疗效监测题目：Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate 翻译：以黏蛋白 1-C 抗体- 药物偶联物靶向治疗对KRAS 抑制剂耐药的胰腺癌题目：Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers 翻译：新型叶酸受体α靶向拓扑异构酶1 抑制剂偶联抗体药物AZD5335 的研发：用于治疗叶酸受体α阳性癌症题目：D3-GPC2–Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer 翻译：靶向 D3 - 神经节苷脂- 神经母细胞瘤癌基因同源物2 的嵌合抗原受体T 细胞在神经母细胞瘤及小细胞肺癌临床前模型中兼具安全性与有效性题目：The Impact of JAK1Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer 翻译：JAK1致病性基因变异及主要组织相容性复合体Ⅰ类分子表达对子宫内膜癌患者免疫检查点抑制剂治疗应答的影响题目：Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial 翻译：雌激素受体低表达转移性乳腺癌的预后及生物学特征：一项多中心队列研究与TONIC 试验结果 JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE（本周无更新） 3.内分泌学与代谢 LANCET DIABETES & ENDOCRINOLOGY（本周无更新） 4.呼吸病学 LANCET RESPIRATORY MEDICINE（本周无更新） 5.心血管病学 EUROPEAN HEART JOURNAL 题目：Atrial fibrillation in former world-class rowers: role of environmental and genetic factors 翻译：前世界级赛艇运动员的心房颤动：环境与遗传因素的作用题目：Hypokalaemia and atrial fibrillation detected by implanted loop recorders 翻译：植入式循环记录仪检出的低钾血症与心房颤动题目：Transient anticholinergic burden and out-of-hospital cardiac arrest: a case-crossover study 翻译：一过性抗胆碱能药物负荷与院外心脏骤停的关联性：一项病例交叉研究题目：Circadian patterns of atrial fibrillation and disease progression assessed by implanted loop recorders 翻译：基于植入式循环记录仪评估心房颤动的昼夜节律模式及疾病进展题目：Atrial fibrillation and atherosclerosis cause different vascular brain lesions on magnetic resonance imaging 翻译：心房颤动与动脉粥样硬化在磁共振成像中所致脑血管病变的差异特征 CIRCULATION 题目：Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome 翻译：氧化磷脂、脂蛋白（a）与急性冠状动脉综合征患者的心血管结局题目：Leveraging a Genetic Proxy to Investigate the Effects of Lifelong Cardiac Sodium Channel Blockade 翻译：利用遗传替代标志物探究终身心脏钠通道阻滞的效应题目：High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia: The First-in-Human VCAS Trial 翻译：高压局灶性脉冲电场消融治疗瘢痕相关性室性心动过速：首个人体VCAS 试验题目：Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy 翻译：心肌过度收缩与氧化应激导致肥厚型心肌病患者肌酸激酶功能异常 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（本周无更新） 6.传染病学 LANCET INFECTIOUS DISEASES 题目：Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study 翻译：新冠疫情后美国儿童地方性病毒再流行的动态变化（2022—2023年）：一项前瞻性、多中心、纵向免疫流行病学监测研究题目：Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial 翻译：索托维单抗对比常规治疗用于新冠病毒感染住院患者的疗效：RECOVERY随机、对照、开放标签平台试验题目：A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial 翻译：含氯法齐明 - 利福喷丁的3 个月方案治疗药物敏感性结核病与标准治疗的对比：Clo-Fast随机、开放标签2c 期临床试验题目：Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories 翻译：2021—2022年全球应对抗菌药物耐药性的政策措施：一项覆盖161 个国家和地区的系统性治理分析题目：Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial 翻译：蒿甲醚 - 苯芴醇、青蒿琥酯- 阿莫地喹、双氢青蒿素- 哌喹及青蒿琥酯- 咯萘啶治疗乌干达6 月龄至10 岁儿童无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签4 期临床试验题目：Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial 翻译：辐射减毒全子孢子疟疾疫苗在加蓬儿童中的安全性、耐受性及保护效力：一项随机、双盲、安慰剂对照2 期试验题目：Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study 翻译：TAK-003 登革热疫苗在2024 年巴西圣保罗登革热疫情中对青少年的保护效果：一项阴性病例对照研究题目：Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial 翻译：利福舒替尼三联疗法对比铋剂联合克拉霉素三联疗法一线治疗中国幽门螺杆菌感染：EVEREST-HPⅢ期、多中心、随机、三模拟、双盲、对照、非劣效性试验 CLINICAL MICROBIOLOGY AND INFECTION 题目：Penicillin V as first-line treatment of pneumonia in primary care: a registry-based study 翻译：青霉素 V 作为基层医疗机构肺炎一线治疗方案的疗效：一项基于登记数据库的研究题目：Towards model-informed precision dosing of intravenous linezolid: a multicentre external evaluation of pharmacokinetic models in critically ill adults 翻译：迈向静脉用利奈唑胺的模型指导精准给药：针对危重症成人患者药代动力学模型的多中心外部验证题目：Diagnostic performance of Xpert MTB/RIF Ultra assay with pulmonary and extrapulmonary specimens: a retrospective evaluation in a low-incidence setting in Finland 翻译：Xpert MTB/RIF Ultra 检测在肺部及肺外标本中的诊断效能：芬兰低发病率地区的回顾性评价题目：Defining epidemiological cutoff values for Brucella melitensis: an European multicentre study 翻译：羊布鲁氏菌流行病学折点的界定：一项欧洲多中心研究题目：In vitroactivity and resistance mechanisms of sulbactam/durlobactam against Acinetobacter baumannii clinical isolates in China (2019–2020) 翻译：舒巴坦 / 杜洛巴坦对中国鲍曼不动杆菌临床分离株的体外抗菌活性及耐药机制研究（2019—2020年）题目：Complex pathways to ceftolozane-tazobactam resistance in clinical Pseudomonas aeruginosaisolates: a genomic epidemiology study 翻译：铜绿假单胞菌临床分离株对头孢洛扎 - 他唑巴坦耐药的复杂通路解析：一项基因组流行病学研究题目：Frailty predicts in-hospital and 1-year outcomes in patients with infective endocarditis 翻译：衰弱状态对感染性心内膜炎患者住院期及1 年预后的预测价值题目：Efficacy and safety of a China-developed live attenuated herpes zoster vaccine in Chinese healthy adults aged 40 years and older: a multicentre, randomized, double-blind, placebo-controlled, phase 3 clinical trial 翻译：国产减毒活带状疱疹疫苗在中国 40 岁及以上健康成人中的有效性与安全性：一项多中心、随机、双盲、安慰剂对照Ⅲ期临床试验题目：Current situation of solid organ transplantation from HIV-positive donors to HIV-positive recipients in Europe: the Spanish perspective 翻译：欧洲 HIV 阳性供体向HIV 阳性受体开展实体器官移植的现状：西班牙视角题目：The effect of remdesivir and nirmatrelvir/ritonavir on mortality in patients hospitalized with COVID-19 during the Omicron era: an emulated target trial 翻译：奥密克戎流行期间瑞德西韦与奈玛特韦/ 利托那韦对新冠病毒感染住院患者死亡率的影响：一项仿真目标试验题目：Randomized clinical trial to evaluate the longitudinal HIV-1 reservoir and inflammation in treatment-naïve people starting dolutegravir/lamivudine versus dolutegravir plus tenofovir alafenamide/emtricitabine 翻译：初治 HIV-1 感染者接受多替拉韦/ 拉米夫定方案与多替拉韦联合丙酚替诺福韦/ 恩曲他滨方案治疗后，病毒储存库及炎症水平的纵向评估：一项随机临床试验题目：Safety and immunogenicity of adjuvanted respiratory syncytial virus vaccine in high-risk transplant recipients: an interventional cohort study 翻译：佐剂呼吸道合胞病毒疫苗在高危移植受者中的安全性与免疫原性：一项干预性队列研究题目：Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trial 翻译：晚期 HIV 感染者接受多替拉韦方案与达芦那韦为基础的三联抗逆转录病毒治疗的免疫重建效果对比：Advanz-4随机临床试验 7.胃肠肝病学 LANCET GASTROENTEROLOGY & HEPATOLOGY（本周无更新） JOURNAL OF HEPATOLOGY 题目：Healthy eating and physical activity significantly lower sex-specific alcohol-attributable liver mortality in the United States 翻译：健康饮食与规律运动可显著降低美国不同性别人群中酒精归因性肝脏疾病死亡率题目：Somatic loss-of-function mutations in CIDEB reduce hepatic steatosis by increasing lipolysis and fatty acid oxidation 翻译：CIDEB基因体细胞功能缺失突变通过增强脂解作用与脂肪酸氧化减轻肝脏脂肪变性题目：Enhanced surveillance, subtyping, and host adaptation analysis reveal genotype-wide zoonotic potential of rat hepatitis E virus 翻译：强化监测、亚型分析及宿主适应性研究揭示鼠戊型肝炎病毒全基因型的人畜共患病潜在风险题目：Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cells 翻译：工程化单克隆抗体托贝韦巴特增强 Fc 受体阳性细胞对乙肝表面抗原的捕获并激活乙肝病毒特异性T 细胞题目：Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial 翻译：依折麦布醇治疗原发性硬化性胆管炎的安全性与有效性：ELMWOODⅡ期随机对照试验题目：Phase II INTEGRIS-PSC trial of bexotegrast, an αvβ6/αvβ1integrin inhibitor, in primary sclerosing cholangitis 翻译：αvβ6/αvβ1整合素抑制剂贝索替格拉斯特治疗原发性硬化性胆管炎的Ⅱ期INTEGRIS-PSC 试验题目：Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acute decompensation of cirrhosis 翻译：受体相互作用蛋白激酶 3（RIPK3）作为预测肝硬化急性失代偿患者预后的新型生物标志物的鉴定与验证题目：Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma 翻译：ADP-A2AFP TCR-T 细胞疗法治疗晚期肝细胞癌或胃肝样腺癌的Ⅰ期临床试验题目：Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma 翻译：蛋白质基因组学图谱预测肝外胆管癌辅助化疗的疗效题目：Patient-derived liver organoids recapitulate liver epithelial heterogeneity and enable precision modeling of alcohol-related liver disease 翻译：患者来源肝类器官可重现肝脏上皮细胞异质性，为酒精相关性肝病提供精准建模工具题目：Restoration of N-glycosylation via leucine-activated leucyl-tRNA synthetase 1 overcomes chemoresistance in intrahepatic cholangiocarcinoma 翻译：通过亮氨酸激活的亮氨酰 - tRNA 合成酶1 恢复N - 糖基化，逆转肝内胆管癌的化疗耐药性题目：Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels 翻译：LONP1 表达下调通过升高乳清酸水平加重代谢相关脂肪性肝炎（MASH）诱导的肝纤维化 GASTROENTEROLOGY 题目：Chemical Perturbations Impacting Histone Acetylation Govern Colorectal Cancer Differentiation 翻译：影响组蛋白乙酰化的化学扰动调控结直肠癌分化进程题目：Selective Urokinase Inhibition Plus Chemotherapy: A Novel Approach to Pancreatic Cancer Treatment via Enhanced Antitumor Immunity and Decreased Metastasis 翻译：选择性尿激酶抑制联合化疗：通过增强抗肿瘤免疫与减少转移治疗胰腺癌的新策略题目：Risk of Pancreatic Cancer in Glycemically Defined New-Onset Diabetes: A Prospective Cohort Study 翻译：血糖定义的新发糖尿病患者胰腺癌发病风险：一项前瞻性队列研究题目：Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC 翻译：英夫利昔单抗早期血药浓度及清除率预测重症急性溃疡性结肠炎英夫利昔单抗挽救治疗的疗效：PREDICT-UC研究结果题目：Low Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet Improves Colonic Barrier Function and Mast Cell Activation in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: A Mechanistic Trial 翻译：低可发酵低聚糖、双糖、单糖及多元醇饮食改善腹泻型肠易激综合征患者结肠屏障功能与肥大细胞活化：一项机制性试验题目：Enhancement of Inpatient Mortality Prognostication With Machine Learning in a Prospective Global Cohort of Patients With Cirrhosis With External Validation 翻译：机器学习模型提升全球肝硬化前瞻性队列患者住院死亡风险预测效能及外部验证题目：A Randomized Trial of Endoscopic Submucosal Dissection vs Transanal Minimally Invasive Surgery in Early Rectal Neoplasms: DSETAMIS-2018 Study 翻译：内镜黏膜下剥离术对比经肛微创手术治疗早期直肠肿瘤的随机对照试验：DSETAMIS-2018研究题目：GastroNet-5M: A Multicenter Dataset for Developing Foundation Models in Gastrointestinal Endoscopy 翻译：GastroNet-5M 数据集：用于开发胃肠内镜基础模型的多中心数据集题目：The Natural History of Gastroesophageal Varices in Children With Portal Hypertension 翻译：门静脉高压症儿童患者食管胃底静脉曲张的自然病程研究 GUT 题目：Circulating HBV RNA and HBsAg seroconversion in patients with chronic HBV infection: a long-term follow-up study starting from childhood in Taiwan 翻译：中国台湾地区慢性乙型肝炎病毒感染患者循环乙肝病毒RNA 与乙肝表面抗原血清学转换：一项始于儿童期的长期随访研究题目：Tracking B cell immunity during perturbation of hepatitis B infection induced by treatment withdrawal 翻译：停药诱导乙型肝炎感染状态扰动过程中B 细胞免疫功能的动态监测题目：Hereditary chronic pancreatitis induced plasticity cooperates with mutant Kras in early pancreatic carcinogenesis 翻译：遗传性慢性胰腺炎诱导的细胞可塑性与突变型Kras 协同促进胰腺癌早期发生题目：Secondary bile acid production by gut bacteria promotes Western diet-associated colorectal cancer 翻译：肠道细菌产生的次级胆汁酸促进西式饮食相关结直肠癌的发生发展题目：Effects of a probiotic fermented dairy product on hippocampal metabolites, structure and function: an 8-week randomised, placebo-controlled trial in healthy women 翻译：益生菌发酵乳制品对健康女性海马代谢物、结构及功能的影响：一项8 周随机安慰剂对照试验题目：PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8+ T cell dysfunction 翻译：磷酸烯醇式丙酮酸羧激酶 1（PCK1）缺失通过12 - 羟基二十碳四烯酸（12-HETE）诱导的CD8⁺ T 细胞功能障碍促进代谢相关脂肪性肝炎相关肝细胞癌（MASH-HCC）进展 HEPATOLOGY 题目：Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study 翻译：基于血清 N - 糖组学分析的慢性乙型肝炎患者肝细胞癌早期筛查、诊断及复发监测：一项队列研究题目：Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma 翻译：空间单细胞蛋白质组图谱解析肝内胆管癌的肿瘤微环境生态系统题目：Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients 翻译：免疫耐受期患者乙肝表面抗原（HBsAg）高水平与肝细胞癌（HCC）发病延迟相关题目：Increased risk of HCC in HBeAg-negative indeterminate phase compared with HBeAg-negative chronic infection 翻译：乙肝 e 抗原（HBeAg）阴性不确定期患者相比HBeAg 阴性慢性感染期患者肝细胞癌发病风险升高 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 题目：Diagnosis of Retrograde Cricopharyngeus Dysfunction Using High Resolution Impedance Manometry and Comparison With Control Subjects 翻译：基于高分辨率阻抗测压的环咽肌功能障碍诊断及与健康对照者的对比研究题目：Comparative Effectiveness of Empiric Treatment for Helicobacter pylori in a Large, Diverse Population in the United States 翻译：美国大规模多样化人群中幽门螺杆菌经验性治疗的疗效对比题目：Long-Term Mortality After Cholecystectomy in a Nationwide Cohort of Swedish Individuals Between 1969 and 2016 翻译：瑞典全国队列研究：1969—2016年胆囊切除术患者的远期死亡率分析题目：Nasal Continuous Positive Airway Pressure to Reduce Hypoxia in Patients With Obesity Undergoing Sedated Upper Gastrointestinal Endoscopy: A Prospective Randomized Trial 翻译：经鼻持续气道正压通气改善肥胖患者镇静状态下上消化道内镜检查的缺氧状况：一项前瞻性随机试验题目：Association of Metabolic Comorbidities With Fibrosis Severity and Fibrosis Regression in Patients With Chronic Hepatitis B 翻译：代谢合并症与慢性乙型肝炎患者肝纤维化严重程度及纤维化逆转的相关性题目：The Vasopressin Biomarker Copeptin Is Linked to Systemic Inflammation and Refines Prognostication in Decompensated Cirrhosis 翻译：血管升压素生物标志物和肽素与全身炎症相关，并可优化失代偿期肝硬化患者的预后评估题目：Transferrin Saturation and Serum Ferritin Are Main Predictors of Liver Iron Content in Subjects With Hyperferritinemia 翻译：转铁蛋白饱和度与血清铁蛋白是高铁蛋白血症患者肝脏铁含量的主要预测指标题目：Microbiological Profile of Bacterial Infections in Patients With Cirrhosis Over Time: A 20-year Territory-wide Study 翻译：肝硬化患者细菌感染的病原谱变迁：一项为期20 年的全区域研究题目：Efficacy of 6-mm and 8-mm Transjugular Intrahepatic Portosystemic Shunt for Variceal Bleeding: A Randomized Controlled Trial 翻译：6mm 与8mm 经颈静脉肝内门体分流术治疗食管胃底静脉曲张破裂出血的疗效对比：一项随机对照试验题目：Comparative Effectiveness of Infliximab vs Ustekinumab for Endoscopic and Transmural Remission in Biologic Naïve Crohn’s Disease 翻译：英夫利昔单抗对比乌司奴单抗治疗初治生物制剂的克罗恩病患者内镜下及透壁缓解的疗效题目：Liver Transplantation Is Associated With a Reduced Risk of Colorectal Dysplasia in Patients With IBD and Concomitant PSC 翻译：肝移植可降低炎症性肠病合并原发性硬化性胆管炎患者的结直肠异型增生风险题目：Defining Radiological Healing in Perianal Fistulizing Crohn’s Disease: A TOpClass Global Expert Delphi Consensus 翻译：肛周瘘管型克罗恩病影像学愈合标准的界定：TOpClass全球专家德尔菲共识题目：Proactive Drug Monitoring Versus Clinically Based Dosing for Endoscopic Healing in Pediatric Crohn’s Disease Receiving Infliximab 翻译：英夫利昔单抗治疗儿童克罗恩病时，主动药物浓度监测对比临床经验给药对内镜下愈合的影响题目：Efficacy of Etrasimod in Ulcerative Colitis: Analysis of ELEVATE UC 52 and ELEVATE UC 12 by Baseline Endoscopic Severity 翻译：依曲莫德治疗溃疡性结肠炎的疗效：基于基线内镜严重程度分层的ELEVATE UC 52 与ELEVATE UC 12 研究分析题目：Symptoms of Constipation: Relationship Between Questionnaires and Diaries and Impact on Quality of Life 翻译：便秘症状：问卷与日记记录的一致性及其对生活质量的影响题目：Multicenter Validation of Video-based Deep Learning to Evaluate Defecation Patterns on 3-dimensional High-definition Anorectal Manometry 翻译：基于视频的深度学习评估三维高分辨率肛门直肠测压排便模式的多中心验证题目：Performance of a Smartphone-based Stool Test for Use in Colorectal Cancer Screening: Population-based Study 翻译：基于智能手机的粪便检测用于结直肠癌筛查的效能：一项人群研究 8.公共卫生和流行病学 LANCET PUBLIC HEALTH（本周无更新） LANCET PLANETARY HEALTH（本周无更新） LANCET GLOBAL HEALTH（本周无更新） 9.微生物学 FUNGAL DIVERSITY（本周无更新） LANCET MICROBE（本周无更新） NATURE MICROBIOLOGY 题目：A Plasmodium-derived nanoparticle vaccine elicits sterile protection against malaria in mice 翻译：疟原虫来源纳米颗粒疫苗诱导小鼠产生抗疟疾无菌保护作用题目：Pneumococcal S protein coordinates cell wall modification and repair to resist host antimicrobials 翻译：肺炎链球菌 S 蛋白协同调控细胞壁修饰与修复以抵抗宿主抗菌防御题目：Streptococcus pneumoniaeS protein activates PBP1a to regulate peptidoglycan remodelling and cell division 翻译：肺炎链球菌 S 蛋白激活青霉素结合蛋白1a（PBP1a）调控肽聚糖重塑与细胞分裂题目：Zoonotic Streptococcusimports glucose to inhibit stringent response and promote growth during meningitis 翻译：人畜共患链球菌摄取葡萄糖以抑制严紧反应并促进脑膜炎发病期的菌株增殖 MICROBIOME 题目：Bacillus amyloliquefaciens PP19 regulation of microbial communities and suppression of Peronophythora litchii 翻译：解淀粉芽孢杆菌 PP19 对微生物群落的调控作用及对荔枝霜疫霉菌的抑制效果题目：Sodium butyrate modulates ocular surface microbiome and attenuates inflammation of meibomian gland dysfunction in ApoE−/− mice 翻译：丁酸钠调控载脂蛋白 E 基因敲除（ApoE⁻/⁻）小鼠眼表微生物组并减轻睑板腺功能障碍相关炎症题目：Synthetic microbial community in pristine environment promotes the growth of the endangered plant Lilium tsingtauense 翻译：原生环境合成微生物群落促进珍稀濒危植物青岛百合生长题目：Gut microbiome-derived indole-3-carboxaldehyde promotes intestinal development via AHR-NRF2 signaling in the early-life of chicks 翻译：雏鸡早期肠道微生物组来源的吲哚 - 3 - 甲醛通过芳香烃受体- 核因子E2 相关因子2（AHR-NRF2）信号通路促进肠道发育题目：Dysbiosis of the gut microbiota in calcium oxalate nephrolithiasis is associated with impaired short-chain fatty acid production and systemic metabolomic disruptions 翻译：草酸钙肾结石患者肠道菌群失调与短链脂肪酸生成受损及全身代谢组紊乱相关题目：Unraveling the interaction between the phageome and bacteriome in the rumen and its role in influencing metabolome dynamics in dairy cows at different lactation stages 翻译：奶牛不同泌乳期瘤胃噬菌体组与细菌组的互作解析及其对代谢组动态变化的影响 10.内科学 JAMA INTERNAL MEDICINE（本周无更新） ANNALS OF INTERNAL MEDICINE 题目：Trends in Cancer Incidence in Younger and Older Adults 翻译：青老年人群癌症发病率变化趋势题目：Primary Care Physician Time Spent in Patient Care: An Observational Study Using Electronic Health Record Logs 翻译：基层医生用于患者诊疗的时间占比：一项基于电子健康记录日志的观察性研究题目：Trends in and Predictors of Physician Attrition From Clinical Practice Across Specialties 翻译：不同专科医生临床执业流失趋势及影响因素分析题目：The Mediterranean Diet for Irritable Bowel Syndrome 翻译：地中海饮食在肠易激综合征中的应用题目：Step Accumulation Patterns and Risk for Cardiovascular Events and Mortality Among Suboptimally Active Adults 翻译：低活动量成年人的步数累积模式与心血管事件及死亡风险的关联题目：Effectiveness of Recombinant Herpes Zoster Vaccine in the U.S. Medicare Population, 2018 to 2019, by Immunocompetence and Prior Receipt of Live Zoster Vaccine 翻译：2018—2019年美国医疗保险人群重组带状疱疹疫苗的保护效力：基于免疫功能状态及既往减毒活疫苗接种史的分层分析题目：Palliative Care Educational App for Family Caregivers of Homebound Patients With Incurable Cancer 翻译：面向居家晚期癌症患者家庭照护者的姑息治疗教育应用程序 11.牙科与口腔外科 JOURNAL OF CLINICAL PERIODONTOLOGY（本周无更新）

细胞疗法免疫疗法并购临床2期临床3期

100 项与恩曲他滨/富马酸磷丙替诺福韦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J05AR17	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
HIV感染	美国	Gilead Sciences, Inc.	2016-04-04

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
获得性免疫缺陷综合征	临床3期	美国	Gilead Sciences, Inc.	2014-01-16
获得性免疫缺陷综合征	临床3期	英国	Gilead Sciences, Inc.	2014-01-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04782180 (CTgov)	临床4期	HIV感染 \| 物质滥用	90	PrEP+Descovy 200Mg 25Mg Tablet (Rapid PrEP group)	簾選遞製廠製糧簾簾遞(蓋鑰築選築膚範觸範繭) = 願壓鏇鹽願選齋觸網積構積醖網窪鹽夢鏇簾範更多	-	2025-12-19
				PrEP+Descovy 200Mg 25Mg Tablet (Rapid PrEP Group)	鏇醖鬱築繭鏇餘餘窪餘(窪膚衊艱觸製蓋製糧願) = 艱製鹽鹽廠鹽廠襯鏇衊憲艱膚齋糧觸憲鹹鏇鹽 (餘繭窪鏇夢憲積壓餘鏇, 繭淵鹹築鹽壓憲網鹽顧 ~ 繭壓鬱糧鏇憲窪範夢顧) 更多
NCT03048422 (IMPAACT 2010 (VESTED), Pubmed \| J Acquir Immune Defic Syndr)	临床3期	bone mineral density \| creatinine clearance	-	Dolutegravir + emtricitabine/tenofovir alafenamide (DTG + FTC/TAF)	窪獵簾糧夢鑰糧淵淵鹹(窪壓窪齋繭觸鬱糧積網) = 網襯蓋構鹽壓築醖艱蓋壓鏇艱衊簾簾願醖範選 (鑰製淵鹹夢憲壓蓋築鹽 )	积极	2024-10-01
				Dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG + FTC/TDF)	窪獵簾糧夢鑰糧淵淵鹹(窪壓窪齋繭觸鬱糧積網) = 窪憲餘糧願鬱蓋窪鏇築壓鏇艱衊簾簾願醖範選 (鑰製淵鹹夢憲壓蓋築鹽 )
NCT04994509 (PURPOSE 1, Pubmed)	临床3期	HIV感染	5,338	Lenacapavir	窪構廠鏇餘築繭餘衊艱(網衊襯顧憲遞廠繭蓋餘) = Injection-site reactions were more common in the lenacapavir group (68.8%) than in the placebo injection group (F/TAF and F/TDF combined) (34.9%); 4 participants in the lenacapavir group (0.2%) discontinued the trial regimen owing to injection-site reactions 淵願築鬱選夢餘獵夢鏇 (鏇餘衊遞願願網餘鏇醖 )	积极	2024-07-24
				Emtricitabine-tenofovir alafenamide (F/TAF)
NCT02815566 (BEING, CTgov)	临床4期	HIV感染 \| 骨质疏松症	34	tenofovir-alafenamide-emtricitabine (Immediate Switch)	醖襯製鏇壓鹽餘憲齋襯(醖構鬱顧憲襯觸窪窪積) = 鏇艱糧窪艱構鹹構鬱衊選衊網鹹憲膚夢蓋淵膚 (觸醖廠壓鑰壓範夢鹽鑰, 積築簾鏇構膚願夢鹽糧 ~ 齋醖鏇獵遞夢網顧鏇築) 更多	-	2023-01-19
				tenofovir-emtricitabine (Delayed Switch)	醖襯製鏇壓鹽餘憲齋襯(醖構鬱顧憲襯觸窪窪積) = 壓鑰齋鹽鑰簾構壓選繭選衊網鹹憲膚夢蓋淵膚 (觸醖廠壓鑰壓範夢鹽鑰, 艱築範網繭夢築築鬱網 ~ 鹹齋餘鹹餘膚遞鬱鬱範) 更多
NCT04097925 (CTgov)	临床2期	HIV感染	30	Descovy+Doravirine	窪夢範網齋積範齋夢積(繭鏇淵淵獵衊糧憲餘鹽) = 繭構繭遞襯壓醖鬱鬱鬱網廠襯構願壓構繭艱積 (夢觸築窪鑰網繭醖獵鑰, 鏇鬱製製餘製顧膚築積 ~ 製夢鑰積願觸積糧遞廠) 更多	-	2022-05-25
NCT04079452 (CTgov)	临床3期	HIV感染	15	FTC+Doravirine+TAF (Doravirine+TAF/FTC Arm (Single Arm))	膚憲獵憲夢繭繭鹽齋獵(醖構窪築獵簾範齋夢網) = 襯繭鑰憲範醖憲齋壓構構夢衊選糧顧淵鹹鑰衊 (衊鏇艱夢製鏇鏇願繭膚, 艱繭範鹹醖憲鹹醖襯繭 ~ 憲繭範鏇蓋繭網窪簾廠) 更多	-	2022-04-28
				FTC+TAF+Doravirie (Doravirie+TAF/FTC Arm (Single Arm))	構衊願願簾遞餘選遞襯(憲夢獵鏇廠襯顧網觸鏇) = 構網鹽鬱構醖製鬱醖製繭襯獵蓋蓋衊壓鏇壓範 (壓積築窪遞艱廠廠艱製, 憲夢醖衊襯選築糧鬱獵 ~ 糧製鬱觸觸衊壓簾積餘) 更多
NCT03048422 (IMPAACT 2010/VESTED \| IMPAACT 2010 (VESTED) \| VESTED, CTgov)	临床3期	HIV感染	643	Efavirenz/emtricitabine/tenofovir disoproxil fumarate (Arm 3: Maternal EFV/FTC/TDF)	糧憲壓願壓遞簾獵網艱 = 範廠艱淵艱觸繭選窪鹽鹹築願鏇積選壓構膚網 (餘積願齋選艱廠齋襯顧, 鹹廠醖鬱淵壓願遞構餘 ~ 願鏇夢網餘壓醖築鬱遞) 更多	-	2021-11-10
				Emtricitabine/tenofovir alafenamide+Dolutegravir (Arm 1: Maternal DTG+FTC/TAF)	選蓋網願壓獵鬱鹽獵願 = 簾鹽糧願齋鑰廠築範鬱襯夢衊醖鏇構膚糧獵願 (艱遞顧選壓壓積鹽窪襯, 憲鹽範積壓艱糧鹽糧製 ~ 繭製選積憲鑰顧餘鬱艱) 更多
NCT02285114 (CTgov)	临床2/3期	HIV感染	41	Boosted PIs+F/TAF (F/TAF+3rd ARV Agent (Cohort 2, Part A - Group 1))	膚廠簾醖淵淵網選憲範(糧獵鑰繭襯築膚糧構觸) = 襯構製淵膚鑰壓鏇淵艱鏇繭襯鏇範鏇網艱鹽網 (簾範獵憲鹽遞鹽獵憲衊, 97.35) 更多	-	2021-01-12
				3rd ARV agent+F/TAF (F/TAF+3rd ARV Agent (Cohort 2, Part A - Group 2))	膚廠簾醖淵淵網選憲範(糧獵鑰繭襯築膚糧構觸) = 衊鏇壓壓艱積廠選選醖鏇繭襯鏇範鏇網艱鹽網 (簾範獵憲鹽遞鹽獵憲衊, 187.96) 更多
NCT02842086 (DISCOVER, CTgov)	临床3期	HIV感染	5,399	placebo+TAF+TDF+TVD (Descovy (DVY))	餘鹹範鏇膚願願獵艱醖 = 壓構顧鹽壓選糧網製齋廠築製顧壓積艱壓鬱鬱 (鬱獵觸蓋襯齋襯壓鑰鏇, 網餘繭鹹繭糧顧鏇鏇鹽 ~ 鬱網獵襯醖壓窪積艱衊) 更多	-	2020-03-17
				placebo+TAF+TDF+TVD (Truvada (TVD))	餘鹹範鏇膚願願獵艱醖 = 選鬱壓廠蓋獵餘鬱醖衊廠築製顧壓積艱壓鬱鬱 (鬱獵觸蓋襯齋襯壓鑰鏇, 願選壓構鑰顧廠廠簾窪 ~ 積獵壓夢積憲膚製憲憲) 更多
NCT02469246 (CTgov)	临床3期	HIV感染	567	placebo+ABC/3TC+F/TAF (F/TAF)	製襯衊觸糧鹹網積醖築 = 繭鹹簾構構繭遞鏇齋鬱遞齋鹽衊遞餘顧壓醖鑰 (繭顧簾範齋選壓製繭憲, 鹽鹽築遞範願夢鹹遞窪 ~ 鹹遞淵製獵鹹鬱壓製範) 更多	-	2018-06-11
				ABC (ABC/3TC)	製襯衊觸糧鹹網積醖築 = 範網醖築醖衊範遞憲築遞齋鹽衊遞餘顧壓醖鑰 (繭顧簾範齋選壓製繭憲, 觸積鏇醖蓋壓選簾膚鹽 ~ 獵窪鹽簾窪網範築壓簾) 更多